SOL Capital Management CO reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 3.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,885 shares of the medical instruments supplier’s stock after selling 130 shares during the period. SOL Capital Management CO’s holdings in Becton, Dickinson and were worth $758,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. increased its position in Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares during the period. JPMorgan Chase & Co. increased its position in Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Wells Fargo & Company MN increased its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the period. Finally, Fundsmith LLP increased its position in Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after buying an additional 71,691 shares during the period. 75.71% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE BDX) traded up 1.34% during midday trading on Friday, reaching $200.88. 529,368 shares of the company were exchanged. The firm’s 50 day moving average price is $198.75 and its 200-day moving average price is $187.49. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a market capitalization of $45.71 billion, a P/E ratio of 58.18 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 EPS. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. Becton, Dickinson and’s payout ratio is currently 83.43%.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/becton-dickinson-and-company-nysebdx-shares-sold-by-sol-capital-management-co/1474317.html.

BDX has been the topic of several research analyst reports. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday. Finally, Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their target price for the stock from $210.00 to $180.00 in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $195.79.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. Insiders sold a total of 44,019 shares of company stock worth $8,368,433 in the last 90 days. 1.40% of the stock is currently owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.